Literature DB >> 21145838

Is HCV RNA analysis at day 7 cost-effective in deciding the duration of therapy in chronic HCV genotype 2/3 infection?

Martin Lagging, Sa Alsiö, Kristoffer Hellstrand, Gunnar Norkrans.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 21145838     DOI： 10.1016/j.jhep.2010.09.038

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  3 in total

1.  Early quantification of HCV core antigen may help to determine the duration of therapy for chronic genotype 2 or 3 HCV infection.

Authors:  A Alsiö; A Jannesson; N Langeland; C Pedersen; M Färkkilä; M R Buhl; K Mørch; J Westin; K Hellstrand; G Norkrans; M Lagging
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-11-24       Impact factor: 3.267

Review 2.  Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations.

Authors:  Martin Lagging; Rune Wejstål; Gunnar Norkrans; Olle Karlström; Soo Aleman; Ola Weiland; Maria Castedal; Filip Josephson
Journal:  Infect Dis (Lond)       Date:  2015-12-01

3.  Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience.

Authors:  Jesper Waldenström; Martti Färkkilä; Karolina Rembeck; Gunnar Norkrans; Nina Langeland; Kristine Mørch; Court Pedersen; Mads Rauning Buhl; Urpo Nieminen; Hannu Nuutinen; Åsa Alsiö; Lars Holmström; Rolf Jungnelius; Katarina Lund; Anders Rubensson; Erik Torell; Johan Westin; Martin Lagging
Journal:  Scand J Gastroenterol       Date:  2015-09-29       Impact factor: 2.423
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.